Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

Allschwil, SWITZERLAND


Ad hoc announcement pursuant to Art. 53 LR

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

Allschwil, Switzerland – January 20, 2022
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals Japan today announce that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved PIVLAZ™ (clazosentan sodium) 150 mg, a selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). The PMDA approval of PIVLAZ is based on a dedicated Japanese Phase 3 program.

Aneurysmal subarachnoid hemorrhage is a condition involving sudden life-threatening bleeding occurring in the subarachnoid space. It is caused by the rupture of an aneurysm – a weak, bulging spot on the wall of a cerebral artery. Emergency procedure (endovascular coiling or microsurgical clipping) is required to stop the hemorrhage. The bleeding and the release of endothelin, a potent vasoconstrictor produced by the neighboring vascular endothelium, can lead to cerebral vasospasm (constriction of arteries in the brain), usually occurring between 4 and 14 days after aneurysm securing. This diminishes blood flow to the brain, and about one third of patients consequently experience worsening of their neurological condition. Cerebral vasospasm is one of the leading secondary causes of disability and death in patients with aSAH.

The incidence of aSAH is estimated to be between 6 and 9 per 100,000 per year worldwide. Notably, aSAH is a significant problem in Japan, with an incidence at least twice as high as in many other countries of the world. The peak incidence in Japanese people occurs in adults in their 50s but can also occur in young people in their 20s and 30s.

PIVLAZ was evaluated in placebo-controlled, randomized, double-blind studies in adult Japanese patients post-aSAH treated by endovascular coiling or microsurgical clipping. PIVLAZ was shown to reduce the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies). The studies confirmed the well documented safety profile of clazosentan which has now been administered to over 2000 patients around the globe. In the registration studies in Japanese patients post-aSAH there were no unexpected safety findings.

Teiji Tominaga, M.D., Ph.D., Professor & Chairman, Department of Neurosurgery, Tohoku University Graduate School of Medicine commented:
“Subarachnoid hemorrhage is a relatively common disease in Japanese people. It is a disease that has a profound effect on patients, their families and workplaces when it occurs in working generations. As a result, there is a great need for new drugs that help with the consequences of this life-changing condition. PIVLAZ is the only drug to demonstrate the prevention of cerebral vasospasm after subarachnoid hemorrhage treatment and the associated new cerebral infarctions and ischemic symptoms. Providing PIVLAZ to Japanese healthcare professionals – the first in the world – is of great significance and I believe we can change the lives of many patients.”

Satoshi Tanaka, Dr Med Sci. and President of Idorsia Pharmaceuticals Japan, commented:
"We are very pleased to bring this landmark drug, PIVLAZ, to patients for the serious consequences of subarachnoid hemorrhage, the first innovation in 25 years. We are grateful to the investigators and skilled staff who have cooperated in conducting pivotal studies and to the patients and their families who have participated in the trials. In anticipation of this approval, my team has advanced the preparation for bringing PIVLAZ to the treating community. Specialized experts are engaging with physicians to support continuity of treatment across Japan, and they are ready to ensure PIVLAZ is utilized effectively. Our distribution network is already established, and our salesforce is in place. I am confident that we will be in an excellent position to make PIVLAZ available to physicians to start treating patients in April 2022.”

Jean-Paul Clozel MD and Chief Executive Officer of Idorsia commented:
“I am so thankful for the perseverance shown by the clazosentan team, particularly the Japanese team led by Satoshi Tanaka. We’ve long believed that Inhibiting the detrimental effects of endothelin during the brain hemorrhage was the key to helping patients avoid the devastating consequences of cerebral vasospasm, and now we have the evidence for Japanese patients. I am grateful to everyone who contributed their expertise to the program that has resulted in the approval of PIVLAZ. After more than 25 years of research, I am relieved and proud that we have prevailed, and that patients can now start to benefit from PIVLAZ.”

About the Japanese Phase 3 program
The Phase 3 program consisted of two double-blind, randomized, placebo-controlled studies assessing the efficacy and safety of clazosentan in reducing vasospasm and vasospasm-related morbidity and mortality events in adult Japanese patients post-aSAH. Patients were randomized 1:1 to receive continuous infusion of either 10 mg/hr of clazosentan or placebo for up to a cumulative maximum of 15 days following the onset of aSAH. The two studies followed the same study design, with one enrolling 221 patients whose aneurysm was secured by surgical clipping and the other enrolling 221 patients whose aneurysm was secured by endovascular coiling.

Both studies showed that clazosentan reduced the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies). The composite endpoint was defined by at least one of the following: All death / New cerebral infarction due to cerebral vasospasm / Delayed ischemic neurologic deficit due to cerebral vasospasm and adjudicated blindly by an independent committee. The effect of clazosentan on all-cause morbidity and mortality was also significant (p<0.05) in a pre-planned analysis of the pooled studies whereas a numerical trend was observed in each study on this endpoint.

In these Phase 3 studies in Japanese patients post-aSAH, there were no unexpected safety findings. Treatment-emergent adverse events occurring in >5% of the clazosentan group (with a difference of >2% compared to placebo) were vomiting and signs of hemodilution or fluid retention (i.e., hyponatremia, hypoalbuminemia, anemia, pleural effusion, brain and pulmonary edema).

Notes to the editor

About PIVLAZ I.V. Infusion liquid 150 mg (clazosentan sodium)
PIVLAZ is an endothelin receptor antagonist (ERA). Endothelin receptors include the endothelin A receptor (ETA) and the endothelin B receptor (ETB), but PIVLAZ is 1000 times more selective for ETA than ETB. It has been reported that both oxidized-hemoglobin-induced endothelin production and endothelin release from red blood cells after the onset of aSAH increase the concentration of endothelin, a potent and sustained vasoconstrictor, and cause cerebral vasospasm via ETA. Therefore, we set out to develop ETA selective antagonist PIVLAZ as a potential drug to prevent cerebral vasospasm.

In the PIVLAZ clinical trial, it was assessed for the first time using not only prevention of cerebral vasospasm but also vasospasm related new infarction and delayed ischemic neurological deficit (Morbidity) and all-cause death (Mortality) as the clinical endpoint, which was the incidence of clinical events. As a result, PIVLAZ showed a significant reduction in the incidence of Morbidity/Mortality events in terms of efficacy, and in terms of safety, there were no adverse events such as hemorrhage that occurred with preexisting aSAH drugs.

About the global registration program “REACT”
In February 2019, Idorsia initiated REACT, a prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH. The phase 3 study builds upon the learnings from the previous clazosentan studies to identify patients at high risk of vasospasm and delayed cerebral ischemia, the optimal dose, the best measure to demonstrate efficacy and an optimized patient management guideline to ensure patient safety.

Approximately 400 patients – treated either with microsurgical clipping or endovascular coiling – are being enrolled at approximately 95 sites across 15 countries. Patients are randomized to receive continuous infusion of either clazosentan (15 mg/hr) or placebo prophylactically, on top of local standard of care, for a period of up to 14 days. REACT is enrolling aSAH patients identified as being at high risk of developing vasospasm and subsequent delayed cerebral ischemia because of high-volume hemorrhage, as assessed by CT scan on hospital admission. Patients experiencing asymptomatic cerebral vasospasm, as measured by angiography, within 14 days of aSAH may also be included. The study is expected to conclude around the end of 2022.

Key literature

  • Fujimura M, et al. Cerebrovasc Dis 2017; 44:59–67
  • Macdonald R L, et al. Stroke. 2012; 43(6):1463-9.
  • Macdonald R L, et al. The Lancet. Neurology, 2011; 10(7):618-625.
  • Macdonald R L, et al. Stroke 2008; 39:3015-3021.
  • Vajkoczy P, et al. Journal of Neurosurgery 2005; 103:9-17.
  • Roux S. et al. J Pharmacol Exp Ther 1997; 283:1110-1118.
  • Clozel M, Watanabe H, Life Sciences 1993; 52(9):825-834.

About Idorsia Pharmaceuticals Japan
Idorsia Pharmaceuticals Japan was established, under the leadership of Dr Satoshi Tanaka, in 2018 to conduct clinical development and prepare the commercialization of Idorsia's innovative and promising compounds for patients in Japan.

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment



Attachments

Press Release PDF